Realizing the Therapeutic Potential of Serine Hydrolases

Abide is a clinical development stage company committed to realizing the therapeutic value of first-in-class serine hydrolase inhibitors to transform the lives of patients with serious unmet medical needs. The 250 enzymes in the serine hydrolase superfamily represent roughly 1% of the human genome and play key roles in physiology and disease. Abide’s initial therapeutic focus is on novel targets in central nervous system signaling pathways.

Unique Discovery Platform for First-in-Class Medicines

Abide’s platform accelerates discovery of novel medicines by leveraging the shared catalytic mechanism of serine hydrolases. This allows us to simultaneously discover and understand the roles these enzymes play in human disease and to identify selective inhibitors from our proprietary and tailored chemical library.

Building a Leading Pipeline

Our lead product candidate, ABX-1431, is a first-in-class, oral, highly selective monoacylglycerol lipase (MGLL) inhibitor with the potential to treat a broad range of central nervous system (CNS) diseases. Our initial focus is on CNS signaling pathways involved in movement disorders such as Tourette Syndrome. We are developing follow-on MGLL inhibitors with differentiated properties to address an even broader range of CNS diseases, and we have discovered novel serine hydrolase inhibitors for targets in diverse therapeutic  areas such as liver disease and oncology.